Oncologists evaluate Chinese herbal medicine

October 19, 2002

This release is also available in French, Spanish, Italian, and German.

An innovative approach to test Chinese herbal medicine using Western research methods has been devised by oncologists in Hong Kong to evaluate the role of herbal medicine in a conventional treatment programme.

Speaking at the European Society for Medical Oncology Congress in Nice, France, today (19 October 2002), Dr Tony Mok from the Chinese University of Hong Kong said, "So many people in China are taking Chinese herbal medicine and we just don't know whether it is effective or safe to use at the same time as conventional medicine. We tend, therefore, to advise against it - but we should know for sure."

Chinese herbal medicine looks at the universal interaction between an individual and the environment and aims to maintain a balance in the Yin and Yang (harmony in the body) in order to preserve health and combat illnesses. There are around 250 types of common herbs to choose from and a combination of any of these will be prescribed to restore the balance. "It is a different concept to conventional medicine which is based on 'one drug for one disease'," he said.

For people with cancer, it is a common belief that Chinese herbal medicine could reduce the toxicity of chemotherapy. "A lot of people in Hong Kong and China go for that," said Dr Mok. The herbalist prescribes a mixture according to the condition of the patient, taking into account his observation on the patient's clinical status.

Because the concept of Chinese herbal medicine is different to Western medicine, they are difficult to compare but Dr Mok and his team have found a way to assimilate research into both, by making the herbal extract into a powder form, along with a placebo powder. The study is conducted according to Good Clinical Practice (GCP) Guideline, a universally accepted standard for clinical research in conventional medicine. In this double-blind randomised trial, neither the herbalist, the conventional physician nor the patients know whether they have been given the herbal extract or the placebo. The patients, while receiving standard adjuvant chemotherapy, were prescribed a combination of herbal extracts (or placebo) for reduction of chemotherapy-induced toxicity. Study endpoints also include treatment tolerance and quality of life. So far, 86 patients with either breast or colon cancer have been recruited into the trial. Dr Mok needs around 150 more people for the study.

Early results indicate a moderate reduction in symptoms such as nausea, vomiting or loss of appetite, although the comparative data will not be available until completion of trial. "We have already demonstrated the feasibility of capturing the information from clinical research on Chinese herbal medicine with this methodology," he said. "And we could find something really useful that could point where we should look for better treatment," he added.

Dr Mok believes there are different ways to measure benefit. "Many doctors regard Chinese herbal medicine as a myth but it is based on a different philosophy to conventional therapies. Both sides need to compromise and be open-minded," he said.
-end-


European Society for Medical Oncology

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.